The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Open accessAbstract
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced antitumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a prodrug of 6‐diazo‐5‐oxo‐l‐norleucine (DON) that blocks glutamine metabolism in myeloid precursor cells can differentiate monocytes into anti‐tumor TAMs, leading to tumor regression in mouse models [56].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Such an environment favors the residency of suppressive myeloid cells such as MDSCs, TANs, and TAMs, all of which contribute to promoting tumor growth, angiogenesis, metastasis, and immune escape (51).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Alternatively, suppressive immune cells, that are metabolically distinct from effector cells, thrive in the TME (1-3).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
Background
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Cell-programmed nutrient partitioning in the tumour microenvironment
Reinfeld, B. I., Madden, M. Z., Wolf, M. M., Chytil, A., Bader, J. E., Patterson, A. R., Sugiura, A., Cohen, A. S., Ali, A., Do, B. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03442-1 · Cited by 1,023
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
“reduced MDSC recruitment and promoted their conversion to inflammatory M1 like macrophages (Oh et al., 2020).”
BackgroundThe complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
Amino acid metabolism in health and disease
Ling, Z.-N., Jiang, Y.-F., Ru, J.-N., Lu, J.-H., Ding, B., & Wu, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01569-3 · Cited by 545
“289 At the same time, the promotion of CD8 + T cell activation and recruitment and signi fi cant inhibition of MDSCs generation and recruitment were observed in models treated with L-DON and JHU-083.”
BackgroundInfluentialTargeting glutamine metabolism as a therapeutic strategy for cancer
Jin, J., Byun, J.-K., Choi, Y.-K., & Park, K.-G. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00971-9 · Cited by 550
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
“207,558 In triple-negative breast cancer, inhibiting glutamine metabolism can increase the presence of activated CD8 + T cells within the tumor.”
BackgroundCAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
“Investigators have also focused on manipulating glutamine metabolism in the TME, and recent studies have highlighted that glutamine antagonists and transient inhibition of glutaminase increase T cell effector function.(254,255) To protect CAR T cells from ROS, investigators have genetically modified T cells to secrete…”
BackgroundEdwards, D. N., Ngwa, V. M., Raybuck, A. L., Wang, S., Hwang, Y., Kim, L. C., Cho, S. H., Paik, Y., Wang, Q., Zhang, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140100 · Cited by 377
“The tumor microenvironment is a diverse landscape, containing a variety of cell types including tumor cells, immune cell populations (lymphocytes, macrophages, natural killer cells, dendritic cells, myeloid-derived suppressor cells [MDSCs], etc.), fibroblasts, and endothelial cells among others (60, 61).”
BackgroundCancer cell metabolism and antitumour immunity
De Martino, M., Rathmell, J. C., Galluzzi, L., & Vanpouille-Box, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-024-01026-4 · Cited by 327
“Although the reasons underlying such an apparent discrepancy have not yet been clarified, it is plausible that TAMs infiltrating different neoplasms such as TNBC and lung carcinoma might express different lactate-sensitive receptors or signal transducers thereof, reflecting the well-established general heterogeneity o…”
InfluentialYang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 352
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Metabolic communication in the tumour–immune microenvironment
Kao, K.-C., Vilbois, S., Tsai, C.-H., & Ho, P.-C. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01002-x · Cited by 349
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“6-diazo-5-oxo-lnorleucine (DON) Blocks glutamine metabolism in myeloid precursor cells 4T1 triple-negative breast cancer model preclinical [56]”
BackgroundEnhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy
Yang, W.-H., Qiu, Y., Stamatatos, O., Janowitz, T., & Lukey, M. J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.04.003 · Cited by 287
STAT proteins in cancer: orchestration of metabolism
Li, Y.-J., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 282
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
“In vivo experiments demonstrated that high ASNS expression promoted nerve invasion and tumor metastasis.”
BackgroundMechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Emerging therapies in cancer metabolism
Xiao, Y., Yu, T.-J., Xu, Y., Ding, R., Wang, Y.-P., Jiang, Y.-Z., & Shao, Z.-M. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.006 · Cited by 256
Ma, G., Zhang, Z., Li, P., Zhang, Z., Zeng, M., Liang, Z., Li, D., Wang, L., Chen, Y., Liang, Y., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00909-0 · Cited by 230
“Additionally, blocking glutamine metabolism also inhibited the expression of IDO in the tumor and myeloid derived cells, resulting in a significant reduction in the levels of kynurenine, further enhancing the anti-tumor immune response [119].”
BackgroundDecoding the spatiotemporal heterogeneity of tumor-associated macrophages
Chu, X., Tian, Y., & Lv, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02064-1 · Cited by 214
“Conversely, inhibition of glutamine metabolism within MDSCs triggers activation-induced cell death and converts them into inflammatory macrophages, suggesting a complex but targeted interaction within the immune system [162].”
BackgroundMyeloid cell-targeted therapies for solid tumours
Goswami, S., Anandhan, S., Raychaudhuri, D., & Sharma, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00737-w · Cited by 220
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 219
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 209
Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential
Xiao, Y.-L., Gong, Y., Qi, Y.-J., Shao, Z.-M., & Jiang, Y.-Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01771-x · Cited by 202
“172 175 As previously mentioned, IDO and TDO are tryptophan catabolism enzymes, and inhibitors of these enzymes have been developed and evaluated in various clinical trials.”
BackgroundRegulatory cells and the effect of cancer immunotherapy
Iglesias-Escudero, M., Arias-González, N., & Martínez-Cáceres, E. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01714-0 · Cited by 191
“More strategies aimed at decreasing the recruitment of MDSCs such as targeting tumor glutamine metabolism [78] and targeting chemokines [79] have been described.”
MethodZheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
“JHU083 is capable of converting immunosuppressive MDSCs and TAMs into tumor-destroying proinflammatory phenotypes [325].”
BackgroundLinking macrophage metabolism to function in the tumor microenvironment
Jin, R., Neufeld, L., & McGaha, T. L. (2025) · Nature Cancer · doi:10.1038/s43018-025-00909-2 · Cited by 166
“…cell metabolic programs and reducing tumor growth in a murine model of colorectal cancer, JHU083 greatly enhances anti-cancer immune responses by activating cytotoxic CD8 + tumor-infiltrating lymphocytes 79 as well as upregulating antigen presentation and immune stimulatory programs in TAMs 79,80 .”
Wang, Z., Liu, F., Fan, N., Zhou, C., Li, D., Macvicar, T., Dong, Q., Bruns, C. J., & Zhao, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589508 · Cited by 180
“Besides, targeting glutamine metabolism with JHU-083 inhibits both tumor growth and metastasis in an immune-dependent manner, including inhibiting infiltration of myeloid-derived suppressor cells, reprogramming myeloid-derived suppressor cells and tumor-associated macrophages from a suppressive to a proinflammatory ph…”
BackgroundHarnessing metabolic dependencies in pancreatic cancers
Encarnación-Rosado, J., & Kimmelman, A. C. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00431-7 · Cited by 174
Metabolic Regulation of Macrophage Activation
Kolliniati, O., Ieronymaki, E., Vergadi, E., & Tsatsanis, C. (2022) · Journal of Innate Immunity · doi:10.1159/000516780 · Cited by 178
Varghese, S., Pramanik, S., Williams, L. J., Hodges, H. R., Hudgens, C. W., Fischer, G. M., Luo, C. K., Knighton, B., Tan, L., Lorenzi, P. L., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0430 · Cited by 171
“More recently, inhibition of glutamine consumption was shown to inhibit myeloid cell functions in tumors, resulting in increased effector T-cell response (36).”
Zhu, L., Zhu, X., & Wu, Y. (2022) · Biomolecules · doi:10.3390/biom12040580 · Cited by 162
“Glutamine metabolism maintains the stability of transcription factor liver activator protein (LAP), a molecule known to regulate the expression of granulocyte colony-stimulating factor (G-CSF), thereby influencing the convening of suppressor cells in the myeloid lineage around the microenvironment [62].”
BackgroundMitochondrial Metabolism Regulation of T Cell–Mediated Immunity
Steinert, E. M., Vasan, K., & Chandel, N. S. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-082015 · Cited by 172
Liu, Y., Zhao, Y., Song, H., Li, Y., Liu, Z., Ye, Z., Zhao, J., Wu, Y. C., Tang, J., & Yao, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217076 · Cited by 160
Clinical development of metabolic inhibitors for oncology
Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R., & Slusher, B. S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148550 · Cited by 167
“JHU083 was also shown to markedly inhibit the generation and recruitment of MDSCs and increase inflammatory tumor-associated macrophages (TAMs) (85).”
BackgroundSelf-citationThe expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 149
The significant role of amino acid metabolic reprogramming in cancer
Liu, X., Ren, B., Ren, J., Gu, M., You, L., & Zhao, Y.-P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01760-1 · Cited by 155
“…promotes the infiltration of MDSCs. [234] Glutamine Glutamine promotes generation and mobilization of MDSCs, but other studies indicates that glutamine deprivation promotes the generation of MDSCs. [235–237] Asparagine Asparagine promotes immunosuppressive function of MDSCs by ERK/ETS2 signaling.”
BackgroundTargeting pancreatic cancer metabolic dependencies through glutamine antagonism
Encarnación-Rosado, J., Sohn, A. S. W., Biancur, D. E., Lin, E. Y., Osorio-Vasquez, V., Rodrick, T. C., González-Baerga, D., Zhao, E., Yokoyama, Y., Simeone, D. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00647-3 · Cited by 148
“Unlike many other tumor types that showed the important contribution of the adaptive immune system 17,19,26 , the antitumor properties of DRP-104 in PDAC were preserved in both the athymic nude and NSG models (Fig.”
Wang, B., Pei, J., Xu, S., Liu, J., & Yu, J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02994-0 · Cited by 156
“GLS, glutaminase; GPT, glutamate pyruvate transaminase; GOT, glutamic-oxaloacetic transaminase; GLUD, glutamate dehydrogenase; CTLs, cytotoxic T lymphocytes; TCA, tricarboxylic acid; TME, tumor microenvironment; AOA: amino-oxyacetic acid immune response [147].”
Control of tumor-associated macrophage responses by nutrient acquisition and metabolism
Zhang, X., Ji, L., & Li, M. O. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.003 · Cited by 146
The therapeutic implications of immunosuppressive tumor aerobic glycolysis
Reinfeld, B. I., Rathmell, W. K., Kim, T. K., & Rathmell, J. C. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00727-3 · Cited by 148
Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
Rais, R., Lemberg, K. M., Tenora, L., Arwood, M. L., Pal, A., Alt, J., Wu, Y., Lam, J., Aguilar, J. M. H., Zhao, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq5925 · Cited by 135
Self-citationHuang, K., Han, Y., Chen, Y., Shen, H., Zeng, S., & Cai, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02205-6 · Cited by 143
Schirrmacher, V. (2020) · Biomedicines · doi:10.3390/biomedicines8110526 · Cited by 143
“These can inhibit myeloid-derived suppressor cells (MDSCs) and enhance tumor-specific immunity [179].”
BackgroundTranscriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
Larionova, I., Kazakova, E., Patysheva, M. R., & Kzhyshkowska, J. G. (2020) · Cancers · doi:10.3390/cancers12061411 · Cited by 138
Guo, C., Qu, X., Tang, X., Song, Y. M., Wang, J., Hua, K., & Qiu, J. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1219 · Cited by 137
Mai, Z., Zhong, J., Zhang, J., Chen, G., Tang, Y., Ma, W., Li, G., Feng, Z., Li, F., Liang, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c11037 · Cited by 128
Hu, X., Ma, Z., Xu, B., Li, S., Yao, Z., Liang, B., Wang, J., Liao, W., Li, L., Wang, C., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12459 · Cited by 136
“Several basic and clinical trials have shown that targeting tumor-dependent glutamine metabolism can effectively inhibit tumor growth [20, 56, 57].”
BackgroundLigon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Self-citationOn the Origin of ATP Synthesis in Cancer
Seyfried, T. N., Arismendi-Morillo, G., Mukherjee, P., & Chinopoulos, C. (2020) · iScience · doi:10.1016/j.isci.2020.101761 · Cited by 127
Qian, Y., Yin, Y., Zheng, X., Liu, Z., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-023-00549-7 · Cited by 128
“This shows enhanced T cell recruitment and reduced proangiogenic and pro-metastatic activities of M2-like macrophages in cancer [154, 193].”
BackgroundCancer cell metabolic reprogramming: a keystone for the response to immunotherapy
Cerezo, M., & Rocchi, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03175-5 · Cited by 124
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids
Pranzini, E., Pardella, E., Paoli, P., Fendt, S., & Taddei, M. L. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.02.004 · Cited by 120
“Indirectly, targeting glutamine metabolism also resensitizes resistant tumors to checkpoint blockade therapy by reducing the transcriptional activity of signal transducer and activator of transcription (STAT)1/3 and consequently decreasing IDO gene expression in tumor cells, thereby enhancing anticancer T cell functio…”
BackgroundCao, X., Geng, Q., Fan, D., Wang, Q., Wang, X., Zhang, M., Zhao, L., Jiao, Y., Deng, T., Liu, H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01704-8 · Cited by 121
“By using an antagonist of glutamine metabolism, researchers found that tumour glutamine restriction restrains the generation and enrichment of MDSCs in the TIME [171].”
BackgroundSelf-citationAn in situ hydrogel-mediated chemo-immunometabolic cancer therapy
Wang, B., Chen, J., Caserto, J. S., Wang, X., & Ma, M. (2022) · Nature Communications · doi:10.1038/s41467-022-31579-8 · Cited by 116
Amino Acid Metabolism in Cancer Drug Resistance
Yoo, H.-C., & Han, J. M. (2022) · Cells · doi:10.3390/cells11010140 · Cited by 122
“Interestingly, blocking glutamine metabolism also suppressed IDO1 expression in both cancer cells and myeloid-derived cells, leading to a marked decrease in kynurenine levels in a mouse melanoma model [121].”
BackgroundInfluentialTargeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond
Zhao, Y., Du, J., & Shen, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157537 · Cited by 131
Tumor‐associated macrophages in immunotherapy
Yan, S., & Wan, G. (2021) · FEBS Journal · doi:10.1111/febs.15726 · Cited by 112
Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets
Nan, D., Yao, W., Huang, L., Liu, R., Chen, X., Xia, W., Sheng, H., Zhang, H., Liang, X., & Lü, Y. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-024-02018-6 · Cited by 124
“It is possible to cause activation-induced cell death in MDSCs and their transformation into inflammatory macrophages by blocking their glu - tamine metabolism [84] (Fig.”
Nanomaterial-enabled metabolic reprogramming strategies for boosting antitumor immunity
Ma, M., Zhang, Y., Pu, K., & Tang, W. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00679h · Cited by 106
Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 111
“Adaptive reprogramming of CD8+ T cells decreased production and recruitment of MDSCs, and remodeling of ECM are observed in these studies, which led to the suppression of the growth and metastasis of tumor cells, sensitivity to ICB, and prolonged survival [169, 176, 177].”
BackgroundMetabolic pathway analysis using stable isotopes in patients with cancer
Bartman, C., Faubert, B., Rabinowitz, J. D., & DeBerardinis, R. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00632-z · Cited by 99
“Interestingly, compounds which broadly inhibit several glutamine-consuming enzymes in addition to glutam-inase have shown remarkable efficacy in several mouse models of cancer 22,126,127 .”
BackgroundMetabolic checkpoints in immune cell reprogramming: rewiring immunometabolism for cancer therapy
Lv, Y., Li, Z., Liu, S., Zhou, Z., Jinling, S., Ba, Y., Weng, S., Zuo, A., Xu, H. W., Luo, P., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02407-6 · Cited by 98
“Activated B cells rely on SREBP for metabolic reprogramming necessary for antibody responses, and generation of germinal centers, memory B cells, and bone marrow plasma cells [187].”
Glutaminase in microglia: A novel regulator of neuroinflammation
Ding, L., Xu, X., Li, C., Wang, Y., Xia, X., & Zheng, J. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.11.038 · Cited by 94
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 98
“Inhibition of glutamine metabolism has been demonstrated to decrease the generation and recruitment of immuno-suppressive MDSCs by reducing tumour-derived CSF-3 secretion while also increasing the expression of MHC II and CD80 on TAMs 291,292 .”
Exosomal cargos-mediated metabolic reprogramming in tumor microenvironment
Tan, S., Yang, Y., Yang, W., Han, Y., Huang, L., Yang, R., Hu, Z., Tao, Y., Liu, L., Li, Y., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02634-z · Cited by 92
“TAMs‑derived exosomal cargos induce metabolic reprogramming Macrophages are the most numerous white blood cells in TME, and TAMs play a key regulatory role in the occurrence and development of tumors.”
BackgroundInfluentialModulation of macrophage metabolism as an emerging immunotherapy strategy for cancer
Dussold, C., Zilinger, K., Turunen, J. R., Heimberger, A. B., & Miska, J. M. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175445 · Cited by 86
“Notably, glutamine inhibition via JHU083 increased the effectiveness of anti-PD1 and anti-CTLA4 check-point blockade in tumors that did not benefit from monotherapy (159).”
BackgroundTumor microenvironmental nutrients, cellular responses, and cancer
Lobel, G. P., Jiang, Y., & Simon, M. C. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.08.011 · Cited by 88
Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
Huang, M., Xiong, D., Pan, J., Zhang, Q., Sei, S., Shoemaker, R. H., Lubet, R. A., Montuenga, L. M., Wang, Y., Slusher, B. S., et al. (2022) · Advanced Science · doi:10.1002/advs.202105885 · Cited by 85
Self-citationMetabolic reprogramming in the immunosuppression of tumor-associated macrophages
Wang, Y., Wang, D., Yang, L., & Zhang, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002426 · Cited by 78
Xu, K., Ma, J., Hall, S. R. R., Peng, R., Yang, H., & Yao, F. (2023) · Theranostics · doi:10.7150/thno.80184 · Cited by 82
Targeting immune cell metabolism in kidney diseases
Basso, P. J., Andrade‐Oliveira, V., & Câmara, N. O. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00413-7 · Cited by 80
Hasan, M. N., Capuk, O., Patel, S. M., & Sun, D. (2022) · Cancers · doi:10.3390/cancers14143331 · Cited by 82
“An altered tumor metabolism creates a TME that depletes critical metabolites, including glucose, glutamine, and tryptophan, and generates immune inhibitory metabolites, including kynurenine [63].”
BackgroundInfluentialKonen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 82
Yokoyama, Y., Estok, T. M., & Wild, R. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0282 · Cited by 80
Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets
Ricci, J. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115206 · Cited by 78
Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer
Rogers, T., & DeBerardinis, R. J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.007 · Cited by 75
Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy
Luo, Z., Eichinger, K. M., Zhang, A., & Li, S. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216396 · Cited by 72
Nanomaterial-Based Repurposing of Macrophage Metabolism and Its Applications
Meng, T., He, D., Han, Z., Shi, R., Wang, Y., Ren, B., Zhang, C., Mao, Z., Luo, G., & Deng, J. (2024) · Nano-Micro Letters · doi:10.1007/s40820-024-01455-9 · Cited by 82
“…HION@Macs degrade into iron to activate the NF-κB pathway Cancer [193] Amino acid DON blocks glutamine metabolism to upregulate M1 TAMs Cancer [194] Lactate, Metabolizing lactate DL@NP-M-M2pep delivers DL to block PI3K/Akt and activate the NF-κB pathway Cancer [195] Lox-loaded Gd/CeO 2 @ZIF-8…”
BackgroundThe Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment
Huang, X., Zhang, F., Wang, X., & Liu, K. (2022) · Cancers · doi:10.3390/cancers14112756 · Cited by 69
“Tregs then recruit MDSCs and promote TAMs proliferation to enhance IDO1-drive immunosuppressive network [19,26].”
BackgroundThe effects of metabolism on the immune microenvironment in colorectal cancer
Chen, X., Ma, Z., Yi, Z., Wu, E., Shang, Z., Tuo, B., Li, T., & Liu, X. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01865-z · Cited by 71
“[9, 10] Furthermore, glutamine enhances cancer cell survival and proliferation through metabolic reprogramming in the TME, [11] thereby promoting cancer progression.”
BackgroundPraharaj, M., Shen, F., Lee, A. J., Zhao, L., Nirschl, T. R., Theodros, D., Singh, A. K., Wang, X., Adusei, K. M., Lombardo, K. A., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1105 · Cited by 71
“…of TAMs and TIMs and validation using both transcriptomics and flow cytometry, we established that JHU083 treatment increases TNF signaling and overall inflammatory signaling, findings that are consistent with the previously reported findings in the 4T1 model of breast cancer (26).”
BackgroundResultInfluentialSelf-citationImmunometabolism of tumor-associated macrophages: A therapeutic perspective
Karimova, A. F., Khalitova, A. R., Suezov, R. V., Markov, N., Mukhamedshina, Y. O., Rizvanov, A. A., Huber, M., Simon, H., & Brichkina, A. I. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115332 · Cited by 70
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
“Moreover, the same compound is able to inhibit the generation and accumulation of MDSCs in the tumour and metastasis sites in different mouse models via reduction of c/EBPβ expression and in turn levels of G-CSF, one of the factors responsible for MDSC recruitment to the TME [179].”
BackgroundXie, W., Chen, B., Wen, H., Xiao, P., Wang, L., Liu, W., Wang, D., & Tang, B. Z. (2022) · ACS Nano · doi:10.1021/acsnano.2c02605 · Cited by 67
Guan, L., Nambiar, D. K., Cao, H., Viswanathan, V., Kwok, S., Hui, A. B., Hou, Y., Hildebrand, R., von Eyben, R., Holmes, B., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1903 · Cited by 66
Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
Zhou, Q., Peng, Y., Ji, F., Chen, H., Kang, W., Chan, L.-S., Gou, H., Lin, Y., Huang, P., Chen, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39571-6 · Cited by 68
“Oh, et al. 28 also showed that the glutamine antagonist JHU083 represses CSF3-driven MDSC in fi ltration, support-ingour fi ndingthat glutaminepromoteschemokinesignalingtoattract MDSC,possiblyinatumor-speci fi cmanner.”
Lakshmanachetty, S., Cruz, J. C., Hoffmeyer, E., Cole, A. P., & Mitra, S. S. (2021) · Cells · doi:10.3390/cells10040893 · Cited by 69
“Recent studies suggest that blocking glutamine/glutaminolysis metabolism prevents the recruitment, generation, and metabolic reprogramming of MDSCs by inhibiting tumor-derived G-CSF secretion and promotes the generation of anti-tumor inflammatory macrophages [67].”
BackgroundMetabolic reprogramming of immune cells in pancreatic cancer progression
Xiang, H., Yang, R., Tu, J., Yan, X., Yang, S., Lv, L., Zhai, X., Zhu, Y., Dong, D., & Tao, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113992 · Cited by 68
Metabolic reprogramming of macrophages in cancer therapy
Wang, X., Zhang, S., Xue, D., Neculai, D., & Zhang, J. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.009 · Cited by 66
Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
Huang, J., Wu, Q., Geller, D. A., & Yan, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04716-0 · Cited by 65
“…acid metabolism 6-Diazo-5-oxo-l -norleucine Inhibiting glutamine metabolism, suppressing IDO expression, and inducing pro-inflammatory macrophages [139] 6-Gingerol Inhibiting ARG expression, promoting iNOS and NO expression, enhancing M1-like polarization, and exerting anti-tumor effect [140]…”
BackgroundCurrent Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 80
Cancer cachexia: molecular basis and therapeutic advances
Tan, Y., Xue, R., Pan, Y., he, Z., Hu, X., Li, Y., Li, K., Zhang, X., Bian, X.-W., & Wang, B. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02331-7 · Cited by 67
Jiang, Z., Hsu, J. L., Li, Y., Hortobágyi, G. N., & Hung, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01197 · Cited by 67
“The role of glutamine metabolism in myeloid-derived suppressor cells (MDSCs) has also been reported; JHU083 reduces the recruitment of MDSCs to TME, induces MDSC apoptosis, promotes the conversion of MDSC to pro-inflammatory M1 macrophage, and renders ICI-resistant tumors sensitive to immunotherapy (106).”
BackgroundTargeting monocytes/macrophages in fibrosis and cancer diseases: Therapeutic approaches
Conte, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108031 · Cited by 64
From metabolic byproduct to immune modulator: the role of lactate in tumor immune escape
Jiang, M., Wang, Y., Zhao, X., & Yu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492050 · Cited by 68
Metadata
- Authors
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UPMC Enterprises (United States) (US)
- Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry (CZ)
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-15
- Volume
- 130
- Issue
- 7
- Pages
- 3865-3884
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3020598614
- Cited by
- 456
- References
- 66
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 77 · 2023: 89 · 2022: 65 · 2021: 49 · 2020: 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH Office of the Director (R01CA229451, S10 OD016374, R01HL141490, R01AI077610, R01CA226765)
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
- Under Armour Women’s Health & Breast Cancer Innovation Grants (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glutamine metabolism, myeloid-derived suppressor cells, tumor microenvironment, tumor-associated macrophages, immunogenic cell death, granulocyte colony-stimulating factor, IDO, kynurenine, immunometabolism, metastasis, antitumor immunity, small molecule inhibitors
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Female, Glutamine, Immunity, Cellular, Immunotherapy, Macrophages, Male, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.